Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Neurogene (NGNE) EBITDA Margin (2018 - 2025)

Historic EBITDA Margin for Neurogene (NGNE) over the last 6 years, with Q1 2025 value amounting to 32398.75%.

  • Neurogene's EBITDA Margin rose 292793100.0% to 32398.75% in Q1 2025 from the same period last year, while for Sep 2025 it was 121637.5%, marking a year-over-year increase of 1451130400.0%. This contributed to the annual value of 8930.27% for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q1 2025, Neurogene's EBITDA Margin is 32398.75%, which was up 292793100.0% from 2176.65% recorded in Q2 2024.
  • In the past 5 years, Neurogene's EBITDA Margin ranged from a high of 434500.0% in Q1 2023 and a low of 2176.65% during Q2 2024
  • Over the past 3 years, Neurogene's median EBITDA Margin value was 17759.09% (recorded in 2025), while the average stood at 116960.38%.
  • In the last 5 years, Neurogene's EBITDA Margin plummeted by 2000000000bps in 2024 and then surged by 292793100bps in 2025.
  • Quarter analysis of 3 years shows Neurogene's EBITDA Margin stood at 434500.0% in 2023, then crashed by -101bps to 2176.65% in 2024, then skyrocketed by 1588bps to 32398.75% in 2025.
  • Its EBITDA Margin was 32398.75% in Q1 2025, compared to 2176.65% in Q2 2024 and 3119.44% in Q1 2024.